Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: an autopsy case.

Sawada Y, Yoshikawa T, Fujii S, Mitsunaga S, Nobuoka D, Mizuno S, Takahashi M, Yamauchi C, Endo I, Nakatsura T.

Hum Vaccin Immunother. 2013 Jun;9(6):1228-33. doi: 10.4161/hv.24179. Epub 2013 Mar 6.

2.

Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.

Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Takayama T, Yamao K, Uesaka K, Furuse J, Kinoshita T, Nakatsura T.

Clin Cancer Res. 2012 Jul 1;18(13):3686-96. doi: 10.1158/1078-0432.CCR-11-3044. Epub 2012 May 10.

3.

Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide.

Tada Y, Yoshikawa T, Shimomura M, Sawada Y, Sakai M, Shirakawa H, Nobuoka D, Nakatsura T.

Int J Oncol. 2013 Oct;43(4):1019-26. doi: 10.3892/ijo.2013.2044. Epub 2013 Jul 31.

4.

HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.

Yoshikawa T, Nakatsugawa M, Suzuki S, Shirakawa H, Nobuoka D, Sakemura N, Motomura Y, Tanaka Y, Hayashi S, Nakatsura T.

Cancer Sci. 2011 May;102(5):918-25. doi: 10.1111/j.1349-7006.2011.01896.x. Epub 2011 Mar 4.

5.

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.

Suzuki S, Shibata K, Kikkawa F, Nakatsura T.

Hum Vaccin Immunother. 2014;10(2):338-43. doi: 10.4161/hv.27217. Epub 2013 Nov 21.

6.

Peptide vaccines for hepatocellular carcinoma.

Nobuoka D, Yoshikawa T, Sawada Y, Fujiwara T, Nakatsura T.

Hum Vaccin Immunother. 2013 Jan;9(1):210-2. doi: 10.4161/hv.22473.

7.

[The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].

Sawada Y, Nakatsura T.

Nihon Rinsho. 2012 Dec;70(12):2136-41. Review. Japanese.

PMID:
23259386
8.

[Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].

Nishimura Y, Nakatsura T, Senju S.

Nihon Rinsho Meneki Gakkai Kaishi. 2008 Oct;31(5):383-91. Review. Japanese.

9.

Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice.

Iwama T, Uchida T, Sawada Y, Tsuchiya N, Sugai S, Fujinami N, Shimomura M, Yoshikawa T, Zhang R, Uemura Y, Nakatsura T.

Biochem Biophys Res Commun. 2016 Jan 1;469(1):138-43. doi: 10.1016/j.bbrc.2015.11.084. Epub 2015 Nov 23.

10.

Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.

Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T.

Int J Oncol. 2015 Jan;46(1):28-36. doi: 10.3892/ijo.2014.2737. Epub 2014 Oct 30.

11.

Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide.

Iwama T, Horie K, Yoshikawa T, Nobuoka D, Shimomura M, Sawada Y, Nakatsura T.

Int J Oncol. 2013 Mar;42(3):831-8. doi: 10.3892/ijo.2013.1793. Epub 2013 Jan 23.

12.

Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.

Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y.

Clin Cancer Res. 2006 May 1;12(9):2689-97.

13.

GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.

Li SQ, Lin J, Qi CY, Fu SJ, Xiao WK, Peng BG, Liang LJ.

Hepatogastroenterology. 2014 Mar-Apr;61(130):278-84.

PMID:
24901124
14.

Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.

Nobuoka D, Motomura Y, Shirakawa H, Yoshikawa T, Kuronuma T, Takahashi M, Nakachi K, Ishii H, Furuse J, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kinoshita T, Komori H, Baba H, Fujiwara T, Nakatsura T.

Int J Oncol. 2012 Jan;40(1):63-70. doi: 10.3892/ijo.2011.1202. Epub 2011 Sep 15.

PMID:
21922136
15.

Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.

Filmus J, Capurro M.

FEBS J. 2013 May;280(10):2471-6. doi: 10.1111/febs.12126. Epub 2013 Jan 31. Review.

16.

Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma.

Suzuki S, Yoshikawa T, Hirosawa T, Shibata K, Kikkawa F, Akatsuka Y, Nakatsura T.

Cancer Sci. 2011 Sep;102(9):1622-9. doi: 10.1111/j.1349-7006.2011.02003.x. Epub 2011 Jul 8.

17.

HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.

Motomura Y, Ikuta Y, Kuronuma T, Komori H, Ito M, Tsuchihara M, Tsunoda Y, Shirakawa H, Baba H, Nishimura Y, Kinoshita T, Nakatsura T.

Int J Oncol. 2008 May;32(5):985-90.

PMID:
18425324
18.

[A case of hepatocellular carcinoma (HCC) with a huge tumor thrombus in the right atrium].

Goto H, Seki M, Hirota K, Asada S, Yamawaki Y, Imaeda T, Doi H, Ito Y.

Rinsho Hoshasen. 1989 Aug;34(8):925-8. Japanese.

PMID:
2555597
19.

Glypican-3: a new target for cancer immunotherapy.

Ho M, Kim H.

Eur J Cancer. 2011 Feb;47(3):333-8. doi: 10.1016/j.ejca.2010.10.024. Epub 2010 Nov 26. Review.

20.

A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma.

Greten TF, Forner A, Korangy F, N'Kontchou G, Barget N, Ayuso C, Ormandy LA, Manns MP, Beaugrand M, Bruix J.

BMC Cancer. 2010 May 17;10:209. doi: 10.1186/1471-2407-10-209.

Items per page

Supplemental Content

Write to the Help Desk